Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	NYX-2925 200 mg Once Daily (QD)	75
Overall Study	STARTED	NYX-2925 50 mg QD	77
Overall Study	STARTED	NYX-2925 10 mg QD	77
Overall Study	STARTED	Placebo QD	72
Overall Study	COMPLETED	NYX-2925 200 mg Once Daily (QD)	73
Overall Study	COMPLETED	NYX-2925 50 mg QD	74
Overall Study	COMPLETED	NYX-2925 10 mg QD	72
Overall Study	COMPLETED	Placebo QD	69
Overall Study	NOT COMPLETED	NYX-2925 200 mg Once Daily (QD)	2
Overall Study	NOT COMPLETED	NYX-2925 50 mg QD	3
Overall Study	NOT COMPLETED	NYX-2925 10 mg QD	5
Overall Study	NOT COMPLETED	Placebo QD	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03219320/flow